
Demo: Healthcare Agent Orchestrator (HAO) for Patient Summarization in Molecular Tumor Boards

Matthias Blondeel* [†]	Noel Codella*
Microsoft Health and Life Sciences [‡]	Microsoft Health and Life Sciences
Sam Preston*	Hao Qiu*
Microsoft Health and Life Sciences	Microsoft Health and Life Sciences
Leonardo Schettini*	Frank Tuan*
Microsoft Health and Life Sciences	Microsoft Health and Life Sciences
Wen-wai Yim*	Smitha Saligrama
Microsoft Health and Life Sciences	Microsoft Health and Life Sciences
Mert Öz	Shrey Jain
Microsoft Health and Life Sciences	Microsoft Health and Life Sciences
Matthew P. Lungren	Thomas Osborne
Microsoft Health and Life Sciences	Microsoft Health and Life Sciences

Abstract

Molecular Tumor Boards (MTBs) are multidisciplinary forums where oncology specialists collaboratively assess complex patient cases to determine optimal treatment strategies. A central element of this process is the patient summary, typically compiled by a medical oncologist, radiation oncologist, or surgeon, or their trained medical assistant, who distills heterogeneous medical records into a concise narrative to facilitate discussion. This manual approach is often labor-intensive, subjective, and prone to omissions of critical information. To address these limitations, we introduce the *Healthcare Agent Orchestrator (HAO)*, a Large Language Model (LLM)-driven AI agent that coordinates a multi-agent clinical workflow to generate accurate and comprehensive patient summaries for MTBs. Evaluating predicted patient summaries against ground truth presents additional challenges due to stylistic variation, ordering, synonym usage, and phrasing differences, which complicate the measurement of both succinctness and completeness. To overcome these evaluation hurdles, we propose *TBFact*, a “model-as-a-judge” framework designed to assess the comprehensiveness and succinctness of generated summaries. Using a benchmark dataset derived from de-identified tumor board discussions, we applied TBFact to evaluate our Patient History agent. Results show that the agent captured 94% of high-importance information (including partial entailments) and achieved a TBFact recall of 0.84 under strict entailment criteria. We further demonstrate that TBFact enables a data-free evaluation framework that institutions can deploy locally without sharing sensitive clinical data. Together, HAO and TBFact establish a robust foundation for delivering reliable and scalable support to MTBs.

1 Introduction

Molecular Tumor Boards (MTBs) are among healthcare’s most complex collaborative workflows, where radiologists, pathologists, oncologists, geneticists, and other specialists align on patient-specific cancer treatment strategies. The backbone of these meetings is a comprehensive yet concise patient

*Equal contribution.

[†]We gratefully recognize additional contributors in Appendix D.

[‡]Correspondence: hlsfrontierteam@microsoft.com

summary that distills heterogeneous records (clinical notes, imaging, pathology, genomics) into a coherent timeline that orients discussion and decision-making. However, manual preparation of these summaries imposes a significant time burden: radiologists and pathologists report mean preparation times of 81.7 and 144.0 minutes respectively [1]. Quality is also variable; the study notes that the inclusion of comorbidities and patient perspectives often falls below average standards, and the quality of case history and pathological information remains inconsistent [1].

While general-purpose large language models have demonstrated impressive capabilities across many domains, they face critical limitations in high-stakes healthcare settings. Precision is critical: even minor hallucinations or inconsistencies can compromise patient safety and decision quality. Effective decision-making also requires multi-modal integration—correlating imaging, pathology, genomics, and structured Electronic Health Record (EHR) data—much of which lies outside the scope of public training corpora. Finally, transparency and traceability are essential: clinicians must understand how conclusions are formed and be able to audit intermediate steps.

To address these challenges, we introduce the *Healthcare Agent Orchestrator*, a modular, LLM-driven multi-agent system that mirrors the collaborative structure of real tumor boards. Rather than relying on a single monolithic model, HAO coordinates specialized agents—each focused on a domain such as patient history, radiology, pathology, staging, or clinical guidelines—while maintaining coherence and explainability through an orchestrator. This design enables grounded reasoning across heterogeneous data sources and aligns with the multidisciplinary nature of oncology care, allowing HAO to expand into other use-cases.

Evaluating the quality of generated patient summaries introduces its own challenges. Common similarity metrics that emphasize surface overlap are insensitive to clinically meaningful differences: two summaries may use different phrasing, ordering, or synonyms while conveying the same facts—or conversely, appear similar while omitting critical details or introducing unsupported claims. We therefore implement *TBFact*, an evaluation framework that operates at the level of *clinical factual claims*, and assess bidirectional entailment between candidate and reference to quantify both *completeness* (coverage of reference facts) and *succinctness* (a precision-oriented proxy that penalizes unsupported or extraneous statements).

2 Healthcare Agent Orchestrator (HAO)

HAO coordinates role-specialized agents through a facilitator (the orchestrator) that manages turn-taking, shared memory, and verification checkpoints. Agents such as *PatientHistory*, *Radiology*, or *ClinicalTrials* focus on complementary functions aligned to MTB workflows. The orchestrator plans and moderates the interaction, dynamically selecting only the agents needed for a case and recording an auditable trail of intermediate results. The interaction model follows a structured group-chat abstraction implemented with Semantic Kernel and Magentic-One, extended for healthcare complexity, and uses Model Context Protocol (MCP) for secure, two-way tool/data connectivity.

Teams-native collaboration experience The user experience is embedded in Microsoft Teams, where clinicians and developers converse with the orchestrator or directly @-mention agents inside a channel or group chat. This reduces workflow switching and lets multi-human, multi-agent conversations unfold in the same thread used for case coordination. Outputs (e.g., patient timelines or draft MTB briefs) are distributable across Microsoft 365 apps (Word, PowerPoint) for rapid handoff to tumor board packets and follow-ups.

Design goals and orchestration rationale HAO is designed around three principles: (i) *precision under specialization*, by engaging only the most relevant agents for a case; (ii) *traceability*, through shared memory, inline citations, and auditable intermediate artifacts; and (iii) *safety-by-design*, via domain-aware verification checkpoints and constrained tool routing. These choices aim to reduce error propagation and over-orchestration noise while preserving the benefits of division of labor across domains (history, radiology, pathology, trials). This flexibility supports diverse use cases—from rapid single-agent timelines to multi-agent workflows for complex cases—while maintaining transparency and alignment with institutional governance.

Real-world usage patterns A clinical assistant can invoke the *PatientHistory* agent alone to rapidly generate a concise, citation-backed timeline as an MTB opening brief. For complex cases or deeper analysis, the orchestrator can engage multiple agents in sequence to produce a more comprehensive report. This flexibility accommodates diverse information needs: senior specialists




Figure 1: HAO stack diagram illustrating four layers: (i) a Teams-native interface for clinician interaction across Microsoft 365 apps; (ii) an orchestration layer that manages task decomposition, shared memory, and verification checkpoints; and (iii) a set of role-specialized agents paired with domain tools. These agents operate over (iv) a unified data plane integrating EHR, PACS, LIS, institutional knowledge, and external sources.

can request clarifications during meetings, while assistants with partial context can bootstrap high-quality summaries that remain traceable to their sources.

3 TBFact: Measuring Quality in MTB Summaries

Factuality evaluation for long, information-dense outputs commonly adopts a *decompose-then-verify* strategy [2], where choosing the right *unit of analysis* is critical. Concurrent work such as FactEHR explores this paradigm for clinical notes, pairing atomic fact decomposition with LLM-based model-as-a-Judge entailment to compute fact-precision and (weighted) fact-recall [3].

However, claim extraction introduces challenges of ensuring consistent coverage of verifiable content, maintaining entailment fidelity, and handling decontextualization [2]. Evidence favors *fine-grained, explicitly delimited units*: on a broad benchmark, *claim-triplets* improve hallucination detection over sentence- or sub-sentence checks with strong human alignment [4], and in adjacent retrieval settings, *proposition-level* indexing (concise, self-contained factoids) improves retrieval and downstream QA [5].

Motivated by these insights, TBFact adopts short, natural-language *clinical factual claims*, defined as statements that can be objectively verified as true or false based on empirical evidence or reality [6]. TBFact builds on RadFact [7], adapting its principles to text-only healthcare interactions, and introducing two key extensions: (i) importance stratification to prioritize clinically salient information, and (ii) explicit categorization of mismatches into omissions and unsupported claims. While rubric-based frameworks like HealthBench [8] also aim to assess inclusion of clinically relevant aspects, TBFact achieves this through automated fact extraction rather than curated rubrics—enabling scalable, clinically meaningful evaluation without manual rubric authoring.

TBFact’s evaluation pipeline has four main stages:

- Claim Extraction:** Both reference and candidate summaries are decomposed into *clinical factual claims*. These units are independently verifiable and granular enough to reveal omissions or unsupported additions; no fixed ontology schema is required.
- Importance Classification:** Each extracted fact is assigned, an importance level (*high, medium, low*) based on MTB salience (e.g. actionable biomarkers, staging inflections, treatment response). Importance labels are generated programmatically with an LLM rubric.

3. **Bidirectional Entailment and Metric Aggregation:** For each extracted fact, TBFact determines whether it is *fully entailed*, *partially entailed*, or *not entailed* by the counterpart text, then aggregates into (i) Recall, a proxy for *completeness*, and (ii) Precision, a proxy for *succinctness*. Partial credit (0.5) keeps the metric unsaturated and rewards incremental improvements.
4. **Error Attribution:** Non-entailed or partially entailed facts are categorized as *omissions* (missed reference facts) or *unsupported claims* (hallucinations/extraneous details), enabling actionable diagnostics.

While LLMs serve as practical evaluators for complex, open-ended clinical text, their judgments are inherently subjective. Therefore, LLM-based evaluation should be treated as *directional signals*, not absolute scores, and must be paired with human checks (see Section 5.1).

4 Data and Methods

4.1 TB-Bench Dataset

For evaluation, we used *TB-Bench*, a proprietary, de-identified corpus independently curated by a leading healthcare provider partner. TB-Bench aggregates longitudinal materials for 71 oncology patients discussed in MTBs, including tumor board transcripts, exported EHR data, and clinician-authored patient summaries. Inclusion required both a transcript containing a case summary and complete EHR exports (imaging, biomarkers, diagnoses, medications, procedures, and social history).

Reference patient summaries Because original summaries in transcripts were short and varied in format, we applied LLM-based structuring techniques to standardize them into a template comprising a narrative paragraph followed by a chronological timeline of clinical events. This post-processing step reduces variability and ensures fair comparison.

Dataset-verifiable facts During curation, discrepancies were observed between transcript summaries and the available records (e.g., references to notes or studies later excluded in the de-identification pipeline), complicating direct comparison. To avoid penalizing systems for information absent in the dataset snapshot, we restricted evaluation to *dataset-verifiable facts*—claims that can be grounded in the materials included in TB-Bench. We expand on the filtering process in Appendix B.

4.2 PatientHistory agent

The *PatientHistory* agent assembles a citation-backed clinical timeline and summary as input to MTB discussion. It builds on the *Universal Abstraction* framework [9], a zero-shot medical abstraction approach leveraging modular prompt templates to extract oncology attributes (e.g., tumor site, histology, TNM stage, biomarkers, treatments) from unstructured clinical text without task-specific labeling. This foundation enables the agent to retrieve and structure longitudinal information while maintaining grounding to source data for auditability.

4.3 Experiments

We isolate the *PatientHistory* agent to test whether a single specialized agent can match the quality of current MTB summaries, which are short and variable in format. This provides a controlled baseline before exploring multi-agent workflows.

We compare two prompting strategies: a generic baseline and a *specialized* prompt that explicitly instructs chronological organization and prioritization of MTB-critical elements (e.g., biomarkers with dates, treatment lines and responses, imaging-based disease status). Specialized prompting proved the most effective lever for improving completeness during inner-loop iterations.

5 Results

Quantitative performance On *TB-Bench* with specialized prompting, the *PatientHistory* agent achieved **0.84 TBFact recall** on high-importance facts under strict entailment, which translates to inclusion of **94% of high-importance information** when counting partial entailments.⁴ Table 1 summarizes recall across prompting strategies. We report TBFact Recall as the primary metric because, in oncology workflows, omissions of clinically salient information are higher-risk than inclusion of extraneous details. Complete results are reported in Appendix A.

⁴“Strict” counts only fully entailed facts as correct; partial entailments receive fractional credit (0.5).

Configuration	TBFact Recall (All)	TBFact Recall (High-importance)
Generic baseline	0.56	0.66
Specialized prompt	0.71	0.84

Table 1: TBFact recall of patient summaries generated by the *PatientHistory* agent. Importance labels derived via LLM-based rubric.

Specialized prompts improved completeness by aligning outputs with reference expectations, but this also highlights a dependency on reference quality: succinct ground truths can penalize comprehensive outputs. This reinforces the need for standardized, clinically rich benchmarks. Notably, even in single-agent mode, *PatientHistory* matched the information quality of current MTB summaries, suggesting potential time savings without sacrificing completeness, and leaving room for multi-agent workflows to address more complex reasoning tasks. Appendix A gives additional evaluation details.

Qualitative analysis TBFact surfaced common error modes: temporal misalignment, unsupported aggregation, and omissions tied to dataset mismatch. Partial entailments often reflected clinically relevant details absent from the reference, illustrating why partial credit is essential. Examples appear in Appendix C.

5.1 Human Validation Study

To establish TBFact’s reliability as an evaluation metric, we conducted a comprehensive validation study with medically trained annotators across 53 double-annotated facts for human-human comparison, and 71 patient records for system-human comparison from TB-Bench. The study assessed three critical aspects of TBFact:

- **Claim extraction validity:** Annotators verified whether system-extracted claims represented self-contained, clinically meaningful facts. We observed near-perfect inter-annotator agreement (0.999), with system extraction accuracy at 99.9%.
- **Clinical importance classification:** Annotators categorized claims as *high*, *medium*, or *low* importance based on clinical decision-making impact. Agreement was 0.66 (strict) and 0.77 (allowing one-level difference), with system classification matching human judgment in 60% of cases strictly, and 93% when allowing adjacent importance levels.
- **Entailment judgment:** Annotators assessed whether reference data supported each claim. Agreement reached 0.976, with system entailment decisions matching human judgment in 88% of cases.

Critically, end-to-end TBFact F1 scores showed strong correlations with human expert assessments: 55.8% (Kendall), 70.5% (Pearson), and 72.8% (Spearman), validating TBFact as an effective proxy for expert evaluation of clinical factuality and completeness.

6 Discussion

The study addresses two practical pain points in molecular tumor boards (MTBs)—time burden and variable information quality—by pairing a Teams-native agentic workflow (HAO) with a claim-level evaluation framework (TBFact). In single-agent mode, the *PatientHistory* agent matches the information quality of current summaries, capturing 94% of high-importance content when partial entailments are counted and achieving 0.84 strict recall on the same subset. Because TBFact localizes errors to atomic claims and distinguishes omissions from unsupported additions, results are actionable for prompt and policy iteration. The metric’s institution-controlled deployment further suits clinical governance: evaluation can be run locally without sharing patient text, and judgments remain auditable at the claim level. An additional practical insight is that specialized prompting improves completeness by targeting the same families of facts prioritized in reference summaries, which in turn highlights the value of standardized, clinically rich ground truths.

Findings are scoped to a single specialized agent rather than to end-to-end multi-agent orchestration. TBFact relies on model-as-a-judge decisions that, despite substantial agreement with human reviewers, should be treated as directional signals rather than absolute ground truth. Importance labels are LLM-assisted and spot-checked, not exhaustively adjudicated. Finally, evaluation is constrained

to dataset-verifiable facts within a curated, de-identified snapshot; this avoids penalizing missing records but narrows the space of claims considered.

Several extensions are immediate: (i) per-agent evaluation to quantify each role in isolation and, separately, end-to-end assessment of final MTBs recommendations against real case decisions; (ii) multi-agent evaluation tracing cross-agent omissions/distortions with claim-level attribution; (iii) HAO extensions: build on existing agent-agnostic design for further support mixed human-and-agent workflows, and to automate additional clinical use cases (iv) metric refinements (weighted partial credit, category-wise analyses for biomarkers/imaging/therapies); and (v) prospective measurement of edit burden and preparation time in live or simulated tumor boards. Overall, HAO and TBFact offers a practical baseline for MTB preparation—useful today in single-agent mode, with clear headroom for orchestrated, domain-specialized, multi-modal workflows.

References

- [1] Bianca Marrara, Oporuiche Ibekwe, Martin Masika, Kristopher Attwood, Carmelo Gaudio, and Chukwumere Nwogu. Using an adapted tumor board evaluation tool for quality assessment of a thoracic multidisciplinary cancer conference: A pilot study. *JCO Clinical Cancer Informatics*, (7):e2300017, 2023. PMID: 37797277.
- [2] Dasha Metropolitansky and Jonathan Larson. Towards effective extraction and evaluation of factual claims, 2025.
- [3] Monica Munnangi, Akshay Swaminathan, Jason Alan Fries, Jenelle Jindal, Sanjana Narayanan, Ivan Lopez, Lucia Tu, Philip Chung, Jesutofunmi A. Omiye, Mehr Kashyap, and Nigam Shah. Factehr: A dataset for evaluating factuality in clinical notes using llms, 2025.
- [4] Xiangkun Hu, Dongyu Ru, Lin Qiu, Qipeng Guo, Tianhang Zhang, Yang Xu, Yun Luo, Pengfei Liu, Yue Zhang, and Zheng Zhang. Knowledge-centric hallucination detection. In Yaser Al-Onaizan, Mohit Bansal, and Yun-Nung Chen, editors, *Proceedings of the 2024 Conference on Empirical Methods in Natural Language Processing*, pages 6953–6975, Miami, Florida, USA, November 2024. Association for Computational Linguistics.
- [5] Tong Chen, Hongwei Wang, Sihao Chen, Wenhao Yu, Kaixin Ma, Xinran Zhao, Hongming Zhang, and Dong Yu. Dense X retrieval: What retrieval granularity should we use? In Yaser Al-Onaizan, Mohit Bansal, and Yun-Nung Chen, editors, *Proceedings of the 2024 Conference on Empirical Methods in Natural Language Processing*, pages 15159–15177, Miami, Florida, USA, November 2024. Association for Computational Linguistics.
- [6] Jingwei Ni, Minjing Shi, Dominik Stammbach, Mrinmaya Sachan, Elliott Ash, and Markus Leippold. AFaCTA: Assisting the annotation of factual claim detection with reliable LLM annotators. In Lun-Wei Ku, Andre Martins, and Vivek Srikumar, editors, *Proceedings of the 62nd Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)*, pages 1890–1912, Bangkok, Thailand, August 2024. Association for Computational Linguistics.
- [7] Shruthi Bannur, Kenza Bouzid, Daniel C. Castro, Anton Schwaighofer, Anja Thieme, Sam Bond-Taylor, Maximilian Ilse, Fernando Pérez-García, Valentina Salvatelli, Harshita Sharma, Felix Meissen, Mercy Ranjit, Shaury Srivastav, Julia Gong, Noel C. F. Codella, Fabian Falck, Ozan Oktay, Matthew P. Lungren, Maria Teodora Wetscherek, Javier Alvarez-Valle, and Stephanie L. Hyland. Maira-2: Grounded radiology report generation, 2024.
- [8] Rahul K. Arora, Jason Wei, Rebecca Soskin Hicks, Preston Bowman, Joaquin Quiñonero-Candela, Foivos Tsimpourlas, Michael Sharman, Meghan Shah, Andrea Vallone, Alex Beutel, Johannes Heidecke, and Karan Singhal. Healthbench: Evaluating large language models towards improved human health, 2025.
- [9] Cliff Wong, Sam Preston, Qianchu Liu, Zelalem Gero, Jass Bagga, Sheng Zhang, Shrey Jain, Theodore Zhao, Yu Gu, Yanbo Xu, Sid Kiblawi, Roshanthi Weerasinghe, Rom Leidner, Kristina Young, Brian Piening, Carlo Bifulco, Tristan Naumann, Mu Wei, and Hoifung Poon. Universal abstraction: Harnessing frontier models to structure real-world data at scale, 2025.

Appendix

A Importance-stratified TBFact Results

Table 2 gives the full TBFact evaluation results on the *PatientHistory* agent summary using the “specialize” tumor board prompts. As discussed in Section 5, we consider TBFact recall to be the most important metric, ensuring that facts deemed important by a human were also included by the agent. By stratifying based on fact importance, we can see that the agent and humans have higher levels of agreement on the most critical facts to include in the summary.

The TBFact precision metric can be seen as a measure of “succinctness”, ensuring that the agent does not include large amounts of irrelevant information. Both the precision and number of facts ($p_support$ and $r_support$) show that the agent produces more overall facts than the human, indicating that there are additional improvements that can be made to align the agent and human understanding of facts important to the MTB process.

Importance	Precision	Recall	F1	p_support	r_support
Overall	0.446	0.711	0.548	4322	1573
High	0.616	0.838	0.710	2219	816
Medium	0.289	0.644	0.399	1550	517
Low	0.200	0.422	0.272	553	240

Table 2: Overall and importance-stratified TBFact results for the specialized prompts. $p_support$ and $r_support$ give the number of facts identified in the agent- and human-generated summaries, respectively.

B Dataset-Verifiable Fact Filtering

To ensure fair evaluation under conditions where complete patient records are available, we restrict the reference set to *dataset-verifiable facts*—claims from the reference summary that can be grounded in the TB-Bench dataset (EHR exports and clinical notes). This prevents penalizing systems for omissions caused by de-identification or missing records.

Each reference fact is checked for support in the dataset using an LLM-based entailment check (GPT-4.1, temperature 0.0). Facts labeled `Yes` or `Partial` are retained, and unsupported facts are excluded before metric computation. This step ensures TBFact metrics reflect only claims verifiable within the dataset snapshot. Table 3 shows illustrative exclusions.

Algorithm 1 Dataset-Verifiable Fact Filtering

Input: Patients P ; gold facts per patient $G[p]$; curated notes per patient $N[p]$
Output: Filtered gold facts per patient $F[p]$

```
1: for each patient  $p \in P$  do
2:    $notes \leftarrow N[p]$  ▷ All TB-Bench notes for patient  $p$ 
3:    $facts \leftarrow G[p]$  ▷ Facts extracted from reference summary for patient  $p$ 
4:    $supportMask \leftarrow$  array of False of length  $|facts|$ 
5:   for each  $note \in notes$  do
6:      $entailments \leftarrow$  LLMJUDGE( $facts, note$ ) ▷ labels: Yes/No/Partial
7:     for  $i \leftarrow 1$  to  $|facts|$  do
8:       if  $entailments[i] \in \{Yes, Partial\}$  then
9:          $supportMask[i] \leftarrow True$ 
10:      end if
11:    end for
12:  end for
13:   $F[p] \leftarrow \{ facts[i] \mid supportMask[i] = True \}$ 
14: end for
15: return  $F$ 
```

Using Algorithm 1, we find that 75.1% of facts from the tumor board transcripts are supported by the available patient notes, and are retained in the final evaluation.

Excluded Fact	Reason for Exclusion
“Patient reported fatigue during CCNU cycle”	Symptom mentioned in transcript but absent from EHR export
“Plan to continue CCNU and monitor with imaging”	No corresponding plan documented in available records

Table 3: Illustrative examples of excluded facts.

B.1 Hallucination Detection

The TBFact precision metric penalizes facts in the agent-generated summary that are not verifiable given the human-generated summary. These facts can be extraneous information that exists in the patient’s history but which a human decided not to include. However, it is also possible that these are hallucinations that are not supported by available clinical notes. In order to identify possible hallucinations, we apply Algorithm 1 to the agent-generated summary, evaluating whether each fact is supported by the patient’s clinical notes. We find that 96.3% of the facts are supported by the patient notes. Manual inspection of the remaining 3.7% of the facts shows that the majority are cross-note inferences such as “the patient has undergone multiple resections” that are verifiable from the complete history, but not supported by a single clinical note.

C Qualitative Examples of TBFact Evaluation

Table 4 illustrates how TBFact evaluates factual alignment between agent-generated summaries and reference data, including entailment judgments and explanations.

Facts Extracted from Agent Response	Related Excerpt from Reference Text (Ground Truth)	TBFact Judgment
Molecular studies from the 2019-05-18 surgery identified TERT promoter mutation, PTEN mutation, EGFR amplification, CDKN2A/B deletion, monosomy 10, and trisomy 7.	[...] <ul style="list-style-type: none"> Tumor Genetics: <ul style="list-style-type: none"> - EGFR: Amplified - CDKN2A/B: Deleted - PTEN: p.L112R - TERT: c.-146C>T - Chromosome 10: Monosomy - Chromosome 7: Trisomy [...] <ul style="list-style-type: none"> Timeline: <ul style="list-style-type: none"> - 05/18/2019: Diagnosis of multifocal glioblastoma; craniotomy and resection of lesion from right temporal lobe. [...]	Entailed: The summary lists TERT mutation, PTEN mutation, EGFR amplification, CDKN2A/B deletion, monosomy 10, and trisomy 7.
Immunohistochemistry from 2019-05-18 showed GFAP positive, BRAF V600E negative, IDH1 R132H negative, ATRX retained, p53 negative, and a Ki-67 index of 3%.	[...] <ul style="list-style-type: none"> Tumor Genetics: <ul style="list-style-type: none"> - IDH1: Wildtype - BRAF V600E: Negative [...] <ul style="list-style-type: none"> Timeline: <ul style="list-style-type: none"> - 05/18/2019: Diagnosis of multifocal glioblastoma; craniotomy and resection of lesion from right temporal lobe. [...]	Partial Entailment: Some IHC findings match (BRAF negative, IDH1 wildtype) but others (GFAP, p53, Ki-67) are not mentioned in the reference summary.

During the first cycle of CCNU on 2020-04-14, the patient reported significant fatigue, thrombocytopenia, and occasional confusion.	<p>Introduction: [. . .] The patient is experiencing poor tolerance to lomustine and is considering discontinuation due to further disease progression as confirmed by recent MRI scans. [. . .]</p> <p>Timeline: - 04/14/2020 - Present: Lomustine treatment initiated. [. . .]</p>	<p>Partial Entailment: Poor tolerance to lomustine is reported, but specific side effects are not listed in the reference summary.</p>
On 2020-05-16, the plan was to continue CCNU and monitor with imaging.	No related information in the reference text.	<p>No Entailment: No mention in the summary of a plan on 2020-05-16 to continue CCNU with imaging follow-up.</p>

Table 4: Examples of facts extracted from the *PatientHistory* response, along with relevant excerpt from the reference patient summary and *TBFact*'s entailment analysis result for the respective fact.

D Contributors

This work reflects a broad, coordinated effort across engineering, research, and clinical partners. We gratefully acknowledge the many individuals whose expertise, dedication, and collaboration were essential to building, refining, and delivering HAO and its evaluation framework. The following contributors are listed alphabetically.

Contributors

Aiden Gu
 Alberto Santamaria-Pang
 Alexander Ersoy
 Alyssa Unell
 Arun C K
 Chris Burt
 Evan Miller
 Ivan Tarapov
 Jameson Merkow

Kumar Thirumalaiah
 Manoj Kumar
 Mu Wei
 Naiteek Sangani
 Naveen Valluri
 Saumil Shrivastava
 Vincent Fitzgerald
 Will Guyman